Literature DB >> 29159220

Data on atherosclerosis specific antibody conjugation to nanoemulsions.

Geoffrey Prévot1, Martine Duonor-Cérutti2, Mélusine Larivière3, Jeanny Laroche-Traineau3, Marie Josée Jacobin-Valat3, Philippe Barthélémy1, Gisèle Clofent-Sanchez3, Sylvie Crauste-Manciet1.   

Abstract

This article present data related to the publication entitled "Iron oxide core oil-in-water nanoemulsion as tracer for atherosclerosis MPI and MRI imaging" (Prévot et al., 2017) [1]. Herein we describe the engineering in the baculovirus-insect cell system and purification processes of the human scFv-Fc TEG4-2C antibody, specific of platelets within the atheroma plaque. For molecular targeting purpose, atheroma specific antibody was conjugated to nanoemulsions (NEs) using a heterobifunctional linker (DSPE-PEG-maleimide). Atheroma labelling was assayed by immunochemistry on arterial sections from rabbits.

Entities:  

Year:  2017        PMID: 29159220      PMCID: PMC5676083          DOI: 10.1016/j.dib.2017.10.058

Source DB:  PubMed          Journal:  Data Brief        ISSN: 2352-3409


Specifications Table Value of the data Engineering and purification processes of scFv-Fc TEG4-2C antibody for molecular targeting. Maleimide expression at NE vesicle confirmed by spectrophotometer prior antibody grafting. Evaluation of in vitro molecular targeting by immunohistochemistry. Colloidal stability of NE when stored at 4 °C. These data are valuable for the scientific community that work with antibodies.

Data

The dataset of this article provides information about the engineering and purification of a specific human antibody for molecular imaging of atheroma ​[1]. This human antibody was designed with two cysteines at the Fc site for site-specific grafting. Antibody bearing thiol functions was grafted to NEs surface using PEG-maleimide macromolecules. Fig. 1 displays the quantification of maleimide functions by spectrometric assays. Formulation colloidal stability was assayed during 3 months by dynamic light scattering (DLS) (Fig. 2).
Fig. 1

Maleimide quantification expressed at droplet surface of ungrafted emulsion (NE), emulsion formulated with PEG only (NE-PEG) and emulsion formulated with PEG-maleimide (NE-PEG-MAL).

Fig. 2

NE size distribution, on day one (continuous line) and 3 months after formulation (dashed line).

Maleimide quantification expressed at droplet surface of ungrafted emulsion (NE), emulsion formulated with PEG only (NE-PEG) and emulsion formulated with PEG-maleimide (NE-PEG-MAL). NE size distribution, on day one (continuous line) and 3 months after formulation (dashed line).

Experimental design, materials and methods

Generation of recombinant baculovirus expressing scFv-Fc TEG4-2C

ScFv-Fc TEG4-2C was produced using the baculovirus-insect cell system. Briefly, the cDNA encoding TEG4 scFv was amplified by PCR using the following primers: ForVHTEG4 5′-GCTACTTAAGGGTGTCCAGTGTCAGGTGCAGCTGGTGGAGTCTGG-3′ and BacVHTEG4 CCAACCTAGGACGGTCAGCTTGGTCCCTCC in order to delete 6-His and c-myc tags. The PCR fragment was then inserted into a specific transfer vector in frame with a sequence encoding a IgG1 signal peptide at the 5′ end and with a cDNA encoding a human IgG1 Fc domain with 2 extra cysteine residues at the C-terminal end. Sf9 cells were cotransfected by lipofection with the transfer vector and purified viral DNA in the presence of 40 µl of DOTAP liposomal transfection reagent (Roche) [2]. Recombinant viruses were isolated by plaque assay and productive clones were screened by ELISA. The genomic organization of recombinant viruses was controlled by Southern blotting. Sequence of integrated genes was verified after amplification by PCR and sequencing (Eurofins Genomics, Germany).

Production and purification of recombinant scFv-Fc TEG4-2C

Sf9 cells were seeded at a density of 6×105 cells/ml in 400 ml of serum free medium (SF900II, Life Technologies) in roller bottles and infected at a multiplicity of infection of 2 PFU (plaque forming unit) per cell. After 4 days incubation at 28 °C, supernatant was collected and secreted recombinant antibodies were purified on protein A Sepharose (GE, HealthCare). The concentration of purified antibody was determined using bicinchoninic acid (BCA) assay, as recommended by the manufacturer (Pierce) using bovine IgG (Pierce) as a standard.

Maleimide quantification

The number of maleimide functions expressed at droplet surface was determined using the quantitative reaction of maleimide with 2-mercaptoethanol, and the subsequent determination of the unreacted thiol with the photometric Ellman's test described by Moser [3].
Subject areaBiology
More specific subject areaAntibody engineering
Type of dataProtocols and figures
How data was acquiredNE vesicle size was obtained by dynamic light scattering (DLS), maleimide quantification was performed by spectrophotometer
Data formatAnalysed
Experimental factorsScFv-Fc TEG4-2C was produced using the baculovirus-insect cell system then purified on protein A Sepharose
Experimental featuresExperimental description of TEG4 antibody engineering
Data source locationBordeaux, France
Data accessibilityThe data are provided with this article
  3 in total

1.  Cationic liposome-mediated transfection.

Authors:  P L Felgner; G M Ringold
Journal:  Nature       Date:  1989-01-26       Impact factor: 49.962

2.  Quantification of PEG-maleimide ligands and coupling efficiencies on nanoparticles with Ellman's reagent.

Authors:  Marko Moser; Thomas Behnke; Carolina Hamers-Allin; Karin Klein-Hartwig; Jana Falkenhagen; Ute Resch-Genger
Journal:  Anal Chem       Date:  2015-08-28       Impact factor: 6.986

3.  Iron oxide core oil-in-water nanoemulsion as tracer for atherosclerosis MPI and MRI imaging.

Authors:  Geoffrey Prévot; Tina Kauss; Cyril Lorenzato; Alexandra Gaubert; Mélusine Larivière; Julie Baillet; Jeanny Laroche-Traineau; Marie Josée Jacobin-Valat; Laurent Adumeau; Stéphane Mornet; Philippe Barthélémy; Martine Duonor-Cérutti; Gisèle Clofent-Sanchez; Sylvie Crauste-Manciet
Journal:  Int J Pharm       Date:  2017-09-09       Impact factor: 5.875

  3 in total
  1 in total

1.  A Nano-Emulsion Platform Functionalized with a Fully Human scFv-Fc Antibody for Atheroma Targeting: Towards a Theranostic Approach to Atherosclerosis.

Authors:  Samuel Bonnet; Geoffrey Prévot; Stéphane Mornet; Marie-Josée Jacobin-Valat; Yannick Mousli; Audrey Hemadou; Mathieu Duttine; Aurélien Trotier; Stéphane Sanchez; Martine Duonor-Cérutti; Sylvie Crauste-Manciet; Gisèle Clofent-Sanchez
Journal:  Int J Mol Sci       Date:  2021-05-14       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.